Context: Treatment with growth hormone (GH) is considered effective in improving adult height (AH) in Turner syndrome (TS). However, there are few studies comparing AH between treated patients and a concurrent untreated group.
Objective: To assess the efficacy of GH treatment in improving AH in TS and to review previous published studies with treated and untreated groups.
Participants And Methods: We retrospectively analyzed clinical data and AH of a large cohort of GH-treated (n = 168) and untreated (n = 131) patients with TS. Data are shown as median and interquartile range (IQR). We assessed pretreatment variables related with AH and compared our results with 16 studies that also included an untreated group.
Results: The GH-treated group was 6.2 cm taller than the untreated group (AH = 149 cm [IQR 144.5-152.5 cm] vs. 142.8 cm [IQR 139-148 cm], p < 0.001) after 4.9 years of GH treatment with a dose of 0.35 mg/kg/week. AH SDS corrected for target height (TH) was 7.2 cm higher in GH-treated patients. AH SDS ≥-2 was more frequent in GH-treated patients (43%) than in untreated patients (16%, p < 0.001). AH SDS was also more frequently within the TH range in the GH-treated group (52%) than in the untreated group (15%, p < 0.001). Height SDS at start of GH therapy and TH SDS were positively correlated with AH (p < 0.001; R2 = 0.375). Considering the current result together with previous similar publications, a mean AH gain of 5.7 cm was observed in GH-treated (n = 696) versus untreated (n = 633) patients.
Conclusions: Our study strengthens the evidence for efficacy of GH therapy in patients with TS from different populations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000516869 | DOI Listing |
Clin Physiol Funct Imaging
January 2025
Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan.
The present study examined the relationships between trunk tissue distribution, metabolic risk factors, and physical performance in young Japanese individuals using cross-sectional and longitudinal analyses. Thirty-six healthy Japanese men (n = 20, body mass index [BMI]: 20.8 ± 2.
View Article and Find Full Text PDFBMC Womens Health
December 2024
Department of Thyroid and Breast Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
Background: Central obesity and breast cancer (BC) have been identified as relevant by empirical research. The weight-adjusted-waist index (WWI) is a novel methodology for quantifying central obesity. Inspection of the association between WWI and BC in American adult women was the primary goal of the current investigation.
View Article and Find Full Text PDFBMC Geriatr
December 2024
Department of Chemical Pathology, University of Calabar Teaching Hospital, Calabar, Cross River State, Nigeria.
Background: The number of people reaching old age is rising, bringing an increase in age-related diseases like cardiovascular conditions and cognitive dysfunction. Cognitive impairment (CI) impacts various brain functions, affecting daily activities and quality of life. Metabolic syndrome (MetS), a cluster of cardiovascular risk factors, has been implicated in CI.
View Article and Find Full Text PDFSports Med
December 2024
Australian Catholic University, North Sydney, NSW, Australia.
Cell Mol Biol (Noisy-le-grand)
December 2024
Firat University, Faculty of Medicine, Department of Physiology, Elazig, Türkiye.
Vaspin plays a regulatory role in lipid and glucose metabolism and is a therapeutic adipokine against impaired glucose intolerance in obese individuals. We aimed to investigate serum vaspin levels in patients with FMS and whether there was any relationship between vaspin levels and metabolic and clinical parameters in fibromyalgia. A total of 64 female patients who applied to an outpatient clinic due to widespread pain lasting more than three months were included in the study.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!